Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Myelodysplastic Syndromes Clinical Trial

Official title:

A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02074839
• Other study ID #: AG120-C-001
• Status: Recruiting
• Phase: Phase 1
• Start date: March 2014
• Est. completion date: August 2025

Study information

• Verified date: April 2024
• Source: Servier
• Contact: Institut de Recherches Internationales Servier Clinical Studies
• Phone: +33 1 55 72 43 66
• Email: scientificinformation[@]servier.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an IDH1 mutation. The first portion of the study is a dose escalation phase where cohorts of patients will receive ascending oral doses of AG-120 to determine maximum tolerated dose (MTD) and/or the recommended Phase II dose. The second portion of the study is a dose expansion phase where four cohorts of patients will receive AG-120 to further evaluate the safety, tolerability, and clinical activity of the recommended Phase II dose. Additionally, the study includes a substudy evaluating the safety and tolerability, clinical activity, pharmacokinetics, and pharmacodynamics of AG-120 in subjects with relapsed or refractory myelodysplastic syndrome with an IDH1 mutation. Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 291
• Est. completion date: August 2025
• Est. primary completion date: February 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Key Inclusion Criteria:

• Subject must be =18 years of age.

• Subjects must have documented IDH1 R132 gene-mutated advanced hematologic malignancy based on local or central evaluation.

• Subjects must be amenable to serial bone marrow biopsies, peripheral blood sampling, and urine sampling during the study.

• Subjects must have ECOG PS of 0 to 2.

• Platelet count =20,000/µL (Transfusions to achieve this level are allowed).

• Subjects must have adequate hepatic function as evidenced by: Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) =3.0 × ULN, unless considered due to leukemic disease and serum total bilirubin =1.5 x upper limit of normal (ULN), unless considered due to Gilbert's disease or leukemic disease

• Subjects must have adequate renal function as evidenced by a serum creatinine =2.0 × ULN or creatinine clearance >40mL/min based on Cockroft-Gault glomerular filtration rate (GFR)

• Subjects must be recovered from any clinically relevant toxic effects of any prior surgery, radiotherapy, or other therapy intended for the treatment of cancer.

• Female subjects with reproductive potential must have a negative serum pregnancy test within 7 days prior to the start of therapy and on the first day of study drug administration.

Key Exclusion Criteria:

• Subjects who have undergone hematopoietic stem cell transplant (HSCT) within 60 days of the first dose of AG-120, or subjects on immunosuppressive therapy post HSCT at the time of screening, or with clinically significant graft-versus-host disease (GVHD). (The use of a stable dose of oral steroids post HSCT and/or topical for ongoing skin GVHD is permitted.)

• Subjects who received systemic anticancer therapy or radiotherapy <14 days prior to their first day of study drug administration. (Hydroxyurea is allowed prior to enrollment and after the start of AG-120).

• Subjects who received an investigational agent <14 days prior to their first day of study drug administration.

• Subjects who are pregnant or breastfeeding.

• Subjects with an active severe infection or with an unexplained fever >38.5°C during screening visits or on their first day of study drug administration (at the discretion of the Investigator, subjects with tumor fever may be enrolled).

• Subjects with New York Heart Association (NYHA) Class III or IV congestive heart failure or LVEF <40% by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan within approximately 28 days of C1D1.

• Subjects with a history of myocardial infarction within the last 6 months of screening.

• Subjects with a known unstable or uncontrolled angina pectoris.

• Subjects with a known history of severe and/or uncontrolled ventricular arrhythmias.

• Subjects with known unstable or uncontrolled angina pectoris.

• Subjects with heart-rate corrected QT (QTc) interval =450 ms or other factors that increase the risk of QT prolongation or arrhythmic events.

• Patients taking medications that are known to prolong the QT interval

• Subjects with known infection with human immunodeficiency virus (HIV) or active hepatitis B or C.

• Subjects with clinical symptoms suggesting active central nervous system (CNS) leukemia or known CNS leukemia. Evaluation of cerebrospinal fluid is only required if there is a clinical suspicion of CNS involvement by leukemia during screening.

• Subjects with immediately life-threatening, severe complications of leukemia such as uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated intravascular coagulation.

Related Conditions & MeSH terms

• Hematologic Neoplasms
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute
• Myelodysplastic Syndromes
• Neoplasms
• Other IDH1-mutated Positive Hematologic Malignancies
• Preleukemia
• Relapsed or Refractory Acute Myeloid Leukemia (AML)
• Untreated AML

Intervention

Drug:
• AG-120
AG-120 administered continuously as a single agent dosed orally every day of a 28-day cycle. Subjects may continue treatment with AG-120 until disease progression, development of other unacceptable toxicity or hematopoietic stem cell transplant.

Locations

Country	Name	City	State
France	Hopital La Timone	Marseille
France	Hopital Haut-Leveque	Pessac
France	Central Lyon Sud	Pierre-Bénite
France	Institute Gustave Roussly (IGR)	Villejuif
United States	Emory University	Atlanta	Georgia
United States	University of Colorado Denver	Aurora	Colorado
United States	John Hopkins Cancer Center	Baltimore	Maryland
United States	University of Alabama at Birmingham	Birmingham	Alabama
United States	Dana Farber Cancer Institute	Boston	Massachusetts
United States	Massachusetts General Hospital	Boston	Massachusetts
United States	Medical University of South Carolina	Charleston	South Carolina
United States	Northwestern University Medical Hospital	Chicago	Illinois
United States	Cleveland Clinic	Cleveland	Ohio
United States	Ohio State University	Columbus	Ohio
United States	UT Southwestern Medical Center	Dallas	Texas
United States	Karmanos Cancer Center	Detroit	Michigan
United States	City of Hope	Duarte	California
United States	Duke Cancer Center	Durham	North Carolina
United States	MD Anderson Cancer Center	Houston	Texas
United States	Mayo Clinic-Jacksonville	Jacksonville	Florida
United States	University of California-Los Angeles	Los Angeles	California
United States	University of Miami	Miami	Florida
United States	Sarah Cannon Research Institute	Nashville	Tennessee
United States	Cornell Cancer Center	New York	New York
United States	Memorial Sloan Kettering Cancer Center	New York	New York
United States	Mayo Clinic-AZ	Phoenix	Arizona
United States	Oregon Health and Science University	Portland	Oregon
United States	Washington University	Saint Louis	Missouri
United States	University of California-San Francisco	San Francisco	California

Sponsors (1)

Lead Sponsor	Collaborator
Institut de Recherches Internationales Servier

Countries where clinical trial is conducted

United States,  France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety/tolerability: incidence of adverse events.		up to 26 weeks, on average
Primary	Maximum Tolerated Dose and/or the recommended Phase II dose of AG-120 in subjects with advanced hematologic malignancies.		up to 26 weeks, on average
Primary	Assess clinical activity of AG-120 in subjects with relapsed or refractory AML who are enrolled in the Expansion Phase.		up to 26 weeks, on average
Primary	Safety/tolerability of treatment with AG-120 in subjects with relapsed or refractory myelodysplastic syndrome.		up to 26 weeks, on average
Primary	Assess clinical activity of AG-120 in subjects with relapsed or refractory myelodysplastic syndrome.		up to 26 weeks, on average
Secondary	Dose Limiting Toxicities of AG-120 in subjects with advanced hematologic malignancies.		up to 26 weeks, on average
Secondary	Pharmacokinetics of AG-120 in subjects with advanced hematologic malignancies.	Descriptive statistics will be used to summarize PK parameters for each dose group and, where appropriate, for the entire population. Such parameters will include (but are not limited to) maximum concentration (Cmax), time to maximum concentration (Tmax), AUC, elimination half-life, and the fraction of drug excreted unchanged in the urine.	up to 26 weeks, on average
Secondary	Pharmacodynamic relationship of AG-120 and 2-HG.	The potential relationship between plasma exposure of AG-120 and plasma, urine, or bone marrow 2-HG levels will be explored with descriptive and graphical methods.	up to 26 weeks, on average
Secondary	Clinical Activity of AG-120 in advanced hematologic malignancies according to the 2003 revised IWG criteria for AML or the 2006 modified IWG criteria for MDS or MDS/myeloproliferative neoplasms (MPN).		up to 26 weeks, on average
Secondary	Serial blood sampling at specified time points for determination of plasma concentration-time profiles and PK parameters (Cmax) of AG-120 in subjects with R/R MDS.		up to 26 weeks, on average
Secondary	Serial blood sampling at specified time points for determination of plasma concentration-time profiles and PK parameters (Tmax) of AG-120 in subjects with R/R MDS.		up to 26 weeks, on average
Secondary	Serial blood sampling at specified time points for determination of plasma concentration-time profiles and PK parameters (AUC) of AG-120 in subjects with R/R MDS.		up to 26 weeks, on average
Secondary	Blood and bone marrow sampling at specified time points for determination of 2-HG levels to characterize the percent of 2-HG inhibition of AG-120 in plasma and bone marrow.		up to 26 weeks, on average